Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial.
Gatz SA, Harttrampf AC, Brard C, Bautista F, André N, Abbou S, Rubino J, Rondof W, Deloger M, Rübsam M, Marshall LV, Hübschmann D, Nebchi S, Aerts I, Thebaud E, De Carli E, Defachelles AS, Paoletti X, Godin R, Miah K, Mortimer PGS, Vassal G, Geoerger B. Gatz SA, et al. Among authors: marshall lv. Clin Cancer Res. 2024 Feb 16;30(4):741-753. doi: 10.1158/1078-0432.CCR-23-2959. Clin Cancer Res. 2024. PMID: 38051741 Clinical Trial.
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C. Bax DA, et al. Clin Cancer Res. 2009 Sep 15;15(18):5753-61. doi: 10.1158/1078-0432.CCR-08-3210. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737945
Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience.
Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson AD, Moreno L. Morgenstern DA, et al. Among authors: marshall lv. J Pediatr Hematol Oncol. 2014 Apr;36(3):218-23. doi: 10.1097/MPH.0000000000000003. J Pediatr Hematol Oncol. 2014. PMID: 24322496
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, Makin G, Halford SE, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez A, Lyons JF, Boddy AV, Griffin MJ, Yule M, Hargrave D. Moreno L, et al. Among authors: marshall lv. Clin Cancer Res. 2015 Jan 15;21(2):267-73. doi: 10.1158/1078-0432.CCR-14-1592. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370467 Clinical Trial.
Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements.
Carceller F, Bautista FJ, Fowkes LA, Marshall LV, Sirvent SI, Chisholm JC, Pearson AD, Koh DM, Moreno L. Carceller F, et al. Among authors: marshall lv. Pediatr Blood Cancer. 2016 Aug;63(8):1400-6. doi: 10.1002/pbc.26039. Epub 2016 May 3. Pediatr Blood Cancer. 2016. PMID: 27149049 Clinical Trial.
Implementation of mechanism of action biology-driven early drug development for children with cancer.
Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, Skolnik J, Spadoni C, Sterba J, van den Berg H, Uttenreuther-Fischer M, Witt O, Norga K, Vassal G; Members of Working Group 1 of the Paediatric Platform of ACCELERATE. Pearson AD, et al. Among authors: marshall lv. Eur J Cancer. 2016 Jul;62:124-31. doi: 10.1016/j.ejca.2016.04.001. Epub 2016 May 31. Eur J Cancer. 2016. PMID: 27258969 Review.
Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, Moreno L. Carceller F, et al. Among authors: marshall lv. Eur J Cancer. 2016 Nov;67:130-140. doi: 10.1016/j.ejca.2016.08.008. Epub 2016 Sep 21. Eur J Cancer. 2016. PMID: 27662616
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD. Moreno L, et al. Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Expert Opin Drug Discov. 2017. PMID: 28604107 Free article. Review.
From class waivers to precision medicine in paediatric oncology.
Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium. Pearson ADJ, et al. Among authors: marshall lv. Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Lancet Oncol. 2017. PMID: 28677575 Review.
78 results